WO2024036167A3 - Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h - Google Patents

Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h Download PDF

Info

Publication number
WO2024036167A3
WO2024036167A3 PCT/US2023/071865 US2023071865W WO2024036167A3 WO 2024036167 A3 WO2024036167 A3 WO 2024036167A3 US 2023071865 W US2023071865 W US 2023071865W WO 2024036167 A3 WO2024036167 A3 WO 2024036167A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
car
ch25h
methods
enhancing
Prior art date
Application number
PCT/US2023/071865
Other languages
French (fr)
Other versions
WO2024036167A2 (en
Inventor
Serge Fuchs
Noreen MCBREARTY
Zhen LU
Original Assignee
The Trustees Of The University Of Pennyslvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennyslvania filed Critical The Trustees Of The University Of Pennyslvania
Publication of WO2024036167A2 publication Critical patent/WO2024036167A2/en
Publication of WO2024036167A3 publication Critical patent/WO2024036167A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4637—Other peptides or polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure provides modified immune cells or precursors thereof ( e.g., T cells) comprising sequence-defined CAR and cholesterol 25-hydroxylase (CH25H) nucleic acids. Specifically, the CAR comprises an antigen binding domain comprising specificity for a tumor associated antigen (TAA) wherein the TTA is selected from the group consisting of CD19, CD20, CD22, RORI, Mesothelin, CD33/IL3Ra, c-Met, PSMA, PSCA, Glycolipid F77, and EGFRvlll. Compositions and methods of treatment for tumor-related conditions are also provided.
PCT/US2023/071865 2022-08-09 2023-08-08 Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h WO2024036167A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263370877P 2022-08-09 2022-08-09
US63/370,877 2022-08-09

Publications (2)

Publication Number Publication Date
WO2024036167A2 WO2024036167A2 (en) 2024-02-15
WO2024036167A3 true WO2024036167A3 (en) 2024-03-21

Family

ID=89852475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/071865 WO2024036167A2 (en) 2022-08-09 2023-08-08 Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h

Country Status (1)

Country Link
WO (1) WO2024036167A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023596A1 (en) * 1998-10-22 2000-04-27 Board Of Regents, The University Of Texas System Cholesterol 25-hydroxylase
US20210101978A1 (en) * 2016-04-26 2021-04-08 Alector Llc Chimeric receptors and methods of use thereof
WO2021163389A1 (en) * 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023596A1 (en) * 1998-10-22 2000-04-27 Board Of Regents, The University Of Texas System Cholesterol 25-hydroxylase
US20210101978A1 (en) * 2016-04-26 2021-04-08 Alector Llc Chimeric receptors and methods of use thereof
WO2021163389A1 (en) * 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof

Also Published As

Publication number Publication date
WO2024036167A2 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
Brakstad et al. Detection of Staphylococcus aureus by polymerase chain reaction amplification of the nuc gene
Nagamune et al. Distribution of the intermedilysin gene among the anginosus group streptococci and correlation between intermedilysin production and deep-seated infection with Streptococcus intermedius
Schaller et al. Apx toxins in Pasteurellaceae species from animals
Glaus et al. Total synthesis of the bacterial RNA polymerase inhibitor ripostatin B
EP0268652A1 (en) Antitumor compositions and their methods of use
TW200611699A (en) Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
CA2109727A1 (en) Tumor Rejection Antigen Precursors, Tumor Rejection Antigens and Uses Thereof
BRPI0415774A (en) strain of microorganisms and processes of preparation of optimized strains and production of a molecule of interest
WO2024036167A3 (en) Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h
TR200600009T2 (en) Microbial process for the preparation of pravastatin
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
WO2021226321A3 (en) Anti-tumor associated antigen antibodies and uses thereof
EP1957664A1 (en) Method for detecting microorganisms
Tatsuta et al. Total syntheses of polyketide‐derived bioactive natural products
Baharfar et al. Efficient synthesis of rhodanine-based amides via Passerini reaction using tetramethylguanidine-functionalized silica nanoparticles as reusable catalyst
Ohi et al. Synthetic Study on Top-Half (C14-C25) Fragment of Amphidinolide B, a 26-Membered Macrolide
EP1379556A4 (en) Anti pilyrosporum ovale lgy and its uses
Zheng et al. Development of aRhodococcus equi–Escherichia coliPlasmid Shuttle Vector
Perfetti et al. Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis
US4495286A (en) Antibiotic complex producing bacterial culture
NAKAHAMA et al. MICROBIAL CONVERSION OF ANTIBIOTICS. III HYDROXYLATION OF MARIDOMYCIN I AND JOSAMYCIN
Shiroma et al. Improved Synthesis of the AE Ring Segment of Ciguatoxin CTX3C
Zampella et al. Studies towards the synthesis of superstolide A. Synthesis and stereochemical assignment of the C (21) C (26) fragment of superstolide A
Rollett et al. Immunoglobulin heavy chain sequence analysis in Waldenström's macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance
Breneva et al. Modern Features of Pathogenic Leptospira Isolation and Identification in Siberia and the Far East

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23853488

Country of ref document: EP

Kind code of ref document: A2